Brown Shipley& Co Ltd Decreases Stock Holdings in Agilent Technologies, Inc. $A

Key Points

• Brown Shipley & Co Ltd reduced its stake in Agilent Technologies by 8.3% during the second quarter, now owning 21,762 shares valued at approximately $2.57 million.
• Several other investors, including Mirae Asset Global Investments and D.A. Davidson & CO, have increased their stakes in Agilent Technologies during the first quarter.
• Analysts have varying ratings on Agilent Technologies, with Wells Fargo increasing its price target to $150 while maintaining an "overweight" rating, indicating a positive outlook for the stock.

Brown Shipley& Co Ltd lowered its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 8.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,762 shares of the medical research company's stock after selling 1,965 shares during the period. Agilent Technologies accounts for approximately 1.4% of Brown Shipley& Co Ltd's holdings, making the stock its 21st biggest holding. Brown Shipley& Co Ltd's holdings in Agilent Technologies were worth $2,568,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock valued at $4,279,000 after purchasing an additional 4,362 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock valued at $3,606,000 after purchasing an additional 2,371 shares in the last quarter. Alps Advisors Inc. boosted its stake in shares of Agilent Technologies by 29.5% during the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock valued at $1,563,000 after purchasing an additional 3,040 shares in the last quarter. D.A. Davidson & CO. boosted its stake in shares of Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after purchasing an additional 2,207 shares in the last quarter. Finally, LGT Capital Partners LTD. boosted its stake in shares of Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after purchasing an additional 54,302 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on A shares. Wells Fargo & Company boosted their price objective on shares of Agilent Technologies from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Monday, September 15th. Wall Street Zen lowered shares of Agilent Technologies from a "buy" rating to a "hold" rating in a research note on Friday, September 5th. Barclays reissued an "equal weight" rating and set a $125.00 price objective on shares of Agilent Technologies in a research note on Friday, August 29th. Evercore ISI dropped their price objective on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research note on Thursday, August 28th. Finally, Robert W. Baird boosted their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a research note on Thursday, August 28th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $140.08.

Agilent Technologies Stock Up 3.6%

Shares of Agilent Technologies stock opened at $128.21 on Wednesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The stock has a market capitalization of $36.35 billion, a PE ratio of 30.10, a price-to-earnings-growth ratio of 4.04 and a beta of 1.24. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $153.84. The company has a 50-day simple moving average of $121.61 and a two-hundred day simple moving average of $116.02.

Agilent Technologies (NYSE:A - Get Free Report) last issued its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.37. The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be issued a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.99 annualized dividend and a yield of 0.8%. Agilent Technologies's payout ratio is 23.24%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.